The convergence of obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD) is reshaping both the epidemiological forecasting and therapeutic landscape of chronic liver disease. Bayesian age-period-cohort models project rising MASLD incidence through 2050, with young people identified as the demographic experiencing the steepest increases—a trend with direct implications for public health policy given that MASLD/MASH already accounts for a majority share of chronic liver disease burden and serves as a gateway condition to cirrhosis and hepatocellular carcinoma. This forecasting layer, built on retrospective cohort data spanning multiple hospitals and provinces, underscores a shift from reactive clinical management toward anticipatory public health planning, particularly as obesity and diabetes act as compounding risk factors that complicate both disease progression and diagnostic screening (e.g., the well-documented difficulty of ultrasound visualization in obese patients).
On the therapeutic front, the literature reveals a clear trajectory toward incretin-based and multi-receptor agonist pharmacotherapies—semaglutide, tirzepatide, and broader GLP-1 receptor agonist classes—demonstrating meaningful MASH resolution rates (odds ratios exceeding 3 in pooled analyses) and fibrosis improvement with extended treatment duration. These agents are increasingly benchmarked against established cardiometabolic drugs such as SGLT2 inhibitors, reflecting a comparative-effectiveness paradigm in real-world and multicenter studies that treats MASLD as fundamentally a cardiometabolic disease rather than an isolated hepatic condition. This reframes hepatology treatment strategy around shared mechanistic pathways of insulin resistance, hepatic lipid accumulation, and inflammation, positioning diabetes drug classes as dual-purpose interventions for both glycemic control and liver-specific outcomes.
Methodologically, this trend is being validated through an increasingly rigorous evidence infrastructure: systematic reviews and meta-analyses drawing on PubMed, Embase, Scopus, Web of Science, and Cochrane Library, often paired with quality-control frameworks (QUADAS-2, random allocation, blinded outcome assessment) and machine learning models designed to predict MASLD prevalence using accessible clinical indicators—especially valuable for resource-limited screening contexts. Complementary preclinical work using in vivo (BALB/c nude, C57BL/6, Wistar) and in vitro models continues to probe mechanistic links between steatotic liver disease, hepatocarcinogenesis, and candidate biomarkers (e.g., bile acid species), reinforcing a translational pipeline connecting epidemiological forecasting, pharmacologic innovation, and mechanistic discovery aimed at curbing the MASLD-to-liver-cancer continuum.